Symptoms and General Pathology

All Conditions

Neoplasms

Blood and Lymph Conditions

Rare Diseases

Syndrome

Leukemia

Preleukemia

Myelodysplastic Syndromes

Neoplasms by Histologic Type

Hematologic Diseases

Bone Marrow Diseases

Precancerous Conditions

Acute Graft Versus Host Disease

Participants on this arm will see a palliative care specialist twice a week while they are in the hospital and about every other week when they are out of the hospital. If participants see their oncologist less often than every other week while they're out of the hospital, then visits with the palliative care specialist would be timed to occur on the same day as the oncologist visit. Participants will complete a questionnaire about once a month.

Participants will see a palliative care specialist only if they have a referral from their oncologist according to standard clinical care. Participants on this arm will not be discouraged from requesting a consult.

Regular visits with a palliative (supportive) care specialist

Palliative Care Visits

Emily Leytham

Morgan van Ornum

Emily Hoade

Firas El Chaer, MD

The purpose of this study is to estimate the potential benefit of early and continued palliative care (PC) consultation on end of life issues.

Participants in this study will be randomized to either an intervention group or a standard of care group. Participants in the intervention group will participate in regular visits with a palliative (or supportive) care specialist, while participants in the standard of care group will only see palliative care specialists if the clinician requests a referral. All participants will be asked to complete monthly questionnaires regarding their general well-being.

Participants have a greater chance of being assigned to the intervention group than to the standard of care group. On average, in every 5 people randomized, 3 will be randomized to the intervention and 2 will be randomized to standard of care.

Palliative Care Oncology in Patients With Relapsed, Refractory, and High-Risk Leukemias or MDS

Palliative Care Oncology in Patients With Relapsed, Refractory, and High-Risk Leukemias or High-Risk Myelodysplastic Syndrome: Randomized Phase II Study

Location of death (ICU, inpatient floor, hospice, home)

Time from enrollment through death (for participants that die)

Frequency/Number of emergency department visits

Frequency/number and types of transfusions received

Quality of life based on FACT-Leukemia questionnaire, scored from 0 to 176, with a higher score indicating better quality of life

Dates and types of changes to code status (e.g. Do not rescuscitate (DNR) with details)

Whether a GOC discussion occurs while on study, and if so, date and location of discussion

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Palliative Care Oncology in Patients With Relapsed, Refractory, and High-Risk Leukemias or MDS	NCT04482894	Leukemia, Acute AML, Adult ALL, Adult Myelodysplastic...	Palliative Care...	18 Years -	University of Virginia
Palliative Care Oncology in Patients With Relapsed, Refractory, and High-Risk Leukemias or MDS	NCT04482894	Leukemia, Acute AML, Adult ALL, Adult Myelodysplastic...	Palliative Care...	18 Years -	University of Virginia

Spots Global Cancer Trial Database for palliative care visits